Avid Bioservices Inc (CDMO)

[thealias2002]

I've thought about this for a few days and there is a flaw in your argument.

You said Docetaxel performs better on Asian subjects. I'll buy that as I'm sure you can back it up with data, however, here is the flaw; in the p2 trial there were a few sites that raised the bar on overall survival benefit. Being mainly in India, I thought 'perhaps a heavy dose of Asian participants', BUT if that is the case, it only shows that Bavi, too, does well/better with those subjects,.....and that trial was in comparison to Doce as well. With the p3 "failure" and the p2 outperformance (compared to both other Bavi sites and Doce) at certain sites,...to me the question now becomes, 'why were the results so much better in those given test sites', and, 'why did PPHM not review this already to develop a better plan/chance of success for the p3.

I can't find data by trial site......but Bio or someone undoubtedly has it.....